NCT06521190 - ACOU085 for Hearing Loss Prevention in Testicular Cancer Patients Receiving Cisplatin | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 15, 2023

Primary Completion Date

March 31, 2025

Study Completion Date

September 30, 2025

Conditions

Cisplatin-induced Hearing Loss

Interventions

DRUG

ACOU085 (bimokalner)

Transtympanic injection

DRUG

Placebo

Transtympanic injection

Trial Locations (10)

RECRUITING

Dept. of Otolaryngology - Head and Neck Surgery, Tuebingen University, Tübingen

RECRUITING

Dept. of Otolaryngology - Head and Neck Surgery, Dresden University, Dresden

RECRUITING

Dept. of Otolaryngology - Head and Neck Surgery, Essen University, Essen

RECRUITING

Department of Otolaryngology - Head and Neck Surgery, Hamburg University, Hamburg

RECRUITING

Dept. of Otolaryngology - Head and Neck Surgery, Jena University, Jena

RECRUITING

Dept. of Otolaryngology - Head and Neck Surgery, Mannheim University, Mannheim

RECRUITING

Dept. of Otolaryngology - Head and Neck Surgery, Marburg University, Marburg

RECRUITING

Dept. of Hematology and Oncology, Rotkreuzklinikum Munich, Munich

RECRUITING

Dept. of Otolaryngology - Head and Neck Surgery, Munich Technical University, Munich

RECRUITING

Dept. of Otolaryngology - Head and Neck Surgery, Wuerzburg University, Würzburg